UBS ASSET MANAGEMENT AMERICAS LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 21 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
UBS ASSET MANAGEMENT AMERICAS LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2023$198,5000.0%200,0000.0%0.00%
Q1 2023$198,500
+1.5%
200,0000.0%0.00%
Q4 2022$195,641
-99.9%
200,0000.0%0.00%
Q3 2022$192,830,000
-36.9%
200,000
-37.9%
0.00%
Q1 2022$305,476,000
-0.3%
322,0000.0%0.00%
Q4 2021$306,274,000
-35.1%
322,000
-38.3%
0.00%
Q3 2021$472,052,000
-98.5%
522,000
-98.5%
0.00%
-100.0%
Q2 2021$31,606,260,000
+9.5%
35,000,0000.0%0.01%
+7.7%
Q1 2021$28,860,650,000
+4.6%
35,000,0000.0%0.01%0.0%
Q4 2020$27,598,900,000
+7.2%
35,000,000
+9.4%
0.01%
-7.1%
Q3 2020$25,745,920,000
-31.0%
32,000,000
-36.0%
0.01%
-39.1%
Q2 2020$37,300,000,000
-11.9%
50,000,000
-4.8%
0.02%
-23.3%
Q1 2020$42,323,295,000
+31.4%
52,500,000
+64.1%
0.03%
+50.0%
Q4 2019$32,209,920,000
+289011.6%
32,000,000
+156.0%
0.02%
+66.7%
Q4 2016$11,141,000
-75.5%
12,500,000
-69.1%
0.01%
-75.5%
Q3 2016$45,425,00040,500,0000.05%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2022
NameSharesValueWeighting ↓
Worth Venture Partners, LLC 5,324,000$4,995,0003.78%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 57,791,000$53,020,0002.12%
DLD Asset Management, LP 32,500,000$30,048,0002.06%
Castle Creek Arbitrage, LLC 4,504,000$4,161,0001.43%
TENOR CAPITAL MANAGEMENT Co., L.P. 10,000,000$9,372,0000.62%
Graham Capital Management, L.P. 14,636,000$13,509,0000.60%
OAKTREE CAPITAL MANAGEMENT LP 64,452,000$59,704,0000.54%
Context Capital Management, LLC 1,000,000$926,0000.52%
ADVENT CAPITAL MANAGEMENT /DE/ 23,118,000$21,341,0000.52%
WOLVERINE ASSET MANAGEMENT LLC 18,583,000$17,322,0000.21%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders